Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
19 Enero 2023 - 3:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
ALBIREO PHARMA, INC.
(Name of Subject Company)
ALBIREO PHARMA, INC.
(Name of Person Filing Statement)
Common Stock, $0.01 par value per share
(Title of Class of Securities)
01345P106
(CUSIP Number of Class of Securities)
Jason G. Duncan
Chief Legal Officer, General Counsel and Secretary
Albireo Pharma, Inc.
53 State Street, 19th Floor
Boston, Massachusetts, 02109
(857) 254-5555
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
Krishna Veeraraghavan
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, NY 10019-6064
(212) 373-3000
x Check the box
if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Albireo Pharma (NASDAQ:ALBO)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Albireo Pharma (NASDAQ:ALBO)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024